The coming of age of engineered multivalent antibodies

- 36 out of 39 approved therapeutic antibodies are native full-length IgG.
- Antibody engineering may increase potency and improve safety of native antibodies.
- Next generation antibodies may be even more efficient therapeutic molecules.
- 18 engineered antibodies with promising preclinical results are in clinical trials.
- In December 2014, blinatumomab became the first bispecific antibody approved in US.